SynAct Pharma AB Share Price

SYNACT

SE0008241491

Pharmaceuticals

Market Closed - Nasdaq Stockholm 09:30:00 15/09/2026 pm IST			5-day change	1st Jan Change
18.30 ^SEK	-1.72%		-6.92%	-19.03%

07/09	Synact surged in Stockholm, the OMXS30 index rose 0.2 percent	FW
07/09	Rejlers slides on merger plans, OMXS30 index up 0.3 percent	FW

Last Transcript: SynAct Pharma AB

SynAct Pharma AB - Special Call

15/06

More transcripts

Analysts' recommendations: SynAct Pharma AB

18/06	Edison Maintains Its Valuation for Synact Pharma After Trial Results	FW
04/03	Edison Raises Valuation of Synact Pharma - Commissioned Analysis	FW
09/02	Redeye Raises Target Price for Synact Pharma to 31 Kronor (26)	FW
31/25/31	Redeye Raises Target Price for Synact Pharma to 26 Kronor (25)	FW
28/25/28	Edison Initiates Coverage of Synact Pharma, Assigns Value of SEK 36.9 Per Share	FW

More recommendations

Press Releases: SynAct Pharma AB

10/09	SynAct Pharma to Present at Investing in Life Science on September 22	AQ
08/09	SynAct Pharma : Bolagspresentation September 2026	PU
08/09	SynAct Pharma : Company presentation	PU
07/09	SynAct on phase III plans following new ADVANCE data	AQ
07/09	SynAct Pharma : Further analysis of the Phase 2b ADVANCE study reinforces Phase 2b EXPAND results and supports Phase 3 development – FDA discussions on trial design planned for Q4 2026	PU

More press releases

Managers and Directors: SynAct Pharma AB

Manager	Title	Age	Since
Jeppe Øvlesen CEO	Chief Executive Officer	64	01/01/2014
Ann Kristin Led DFI	Director of Finance/CFO	-	01/03/2026
Kirsten Harting CTO	Chief Tech/Sci/R&D Officer	-	15/02/2024

Director	Title	Age	Since
Jeppe Øvlesen BRD	Director/Board Member	64	20/03/2024
Anders Kronborg CHM	Chairman	62	20/03/2024
Sten Scheibye BRD	Director/Board Member	74	20/03/2024

More insiders

SynAct Pharma AB is a manufacturer of biological products. The Company is located in Lund, Sweden. It develops medicines for acute impairment in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.

Employees

Sector

Pharmaceuticals

Calendar

02/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
15/26/15	SEK 18.30	-1.72%	33,702
14/26/14	SEK 18.62	-1.79%	61,725
11/26/11	SEK 18.96	-0.42%	1,05,457
10/26/10	SEK 19.04	-0.73%	96,715
09/26/09	SEK 19.18	-2.44%	1,23,379

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Cap	102.48Cr 10Cr 9.08Cr 8.59Cr 7.77Cr 15Cr 1.01TCr 15Cr 39Cr 509.94Cr 39Cr 39Cr 1.63TCr	P/E 2026 *	-10.9x	P/E 2027 *	-18.7x
Enterprise Value	104.96Cr 11Cr 9.3Cr 8.8Cr 7.96Cr 15Cr 1.03TCr 15Cr 40Cr 522.28Cr 40Cr 39Cr 1.67TCr	EV / Sales 2026 *	23.7x	EV / Sales 2027 *	50.9x
Free-Float	68.66%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	SYNACT	Delayed
CBOE		Real-time
Deutsche Boerse AG	8F8	Delayed
Börse Stuttgart	8F8	Delayed
CBOE		Real-time
Tradegate	8F8	Real-time
Boerse Muenchen	8F8	Real-time

07/09	Synact surged in Stockholm, the OMXS30 index rose 0.2 percent	FW
07/09	Rejlers slides on merger plans, OMXS30 index up 0.3 percent	FW
07/09	Synact Pharma sees support for phase 3 after post hoc analysis	FW
07/09	SynAct Pharma AB Announces Further Analysis Of Phase 2b ADVANCE Study And Supports Phase 3 Development For Resomelagon	CI
03/09	Stockholm stocks rise, Clas Ohlson jumps on earnings, OMXS30 index up 0.6 percent	FW
03/09	Synact Pharma CEO and head of research sell shares for tax reasons	FW
28/08	Synact Pharma to present new preclinical data for resomelagon at WCI	FW
28/08	SynAct Pharma Presents New Resomelagon Preclinical Data On Phase 3-Ready Ra Therapeutic Candidate At The 17th World Congress Of Inflammation 2026	CI
20/08	SynAct Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	Synact Pharma reports narrower operating loss	FW
20/08	Calendar Thursday, August 20	FW
19/08	Synact Pharma signs term sheet with Hipolabor on resomelagon in Brazil	FW
19/08	SynAct Pharma AB and Hipolabor Farmacêutica LTDA Sign Term Sheet for Co-Development and Commercialization Partnership for Treatment of Dengue In Brazil	CI

1 day	-1.72%
1 week	-6.92%
Current month	-8.50%
1 month	-8.22%
3 months	+51.24%
6 months	+4.45%
Current year	-19.03%

1 week	18.2	19.44
1 month	16.84	22.45
Current year	7.05	24.4
1 year	7.05	25.3
3 years	4.98	25.3
5 years	4.98	146
10 years	4.8	146

SynAct Pharma AB Share Price

Stocks

SYNACT

SE0008241491

Pharmaceuticals

Valuation: SynAct Pharma AB

Chart: SynAct Pharma AB

Latest news: SynAct Pharma AB

Last Transcript: SynAct Pharma AB

Analysts' recommendations: SynAct Pharma AB

Press Releases: SynAct Pharma AB

Quotes and Performance

Price Extremes

Managers and Directors: SynAct Pharma AB

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
02/09/26	Jeppe Øvlesen	Sell	Founder	-1,50,000	0.2813%
02/09/26	Thomas Jonassen	Sell	Chief Technology Officer	-3,50,000	0.6563%
10/03/26	Anders Kronborg	Buy	Chairman	2,750	0.0052%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYNACT PHARMA AB	-1.72%	-6.92%	+0.22%	+6.89%	10Cr
ELI LILLY AND COMPANY	-0.19%	+1.09%	+51.85%	+97.36%	1,01300Cr
JOHNSON & JOHNSON	+0.33%	-0.71%	+50.62%	+65.50%	64TCr
ABBVIE INC.	+0.49%	+5.73%	+20.88%	+72.92%	46TCr
ROCHE HOLDING AG	-0.22%	+2.88%	+38.48%	+37.98%	35TCr
NOVARTIS AG	-0.07%	+1.82%	+16.57%	+23.39%	26TCr
ASTRAZENECA PLC	-0.31%	+2.02%	+6.15%	+10.75%	25TCr
AMGEN INC.	-1.53%	-4.46%	+36.90%	+44.08%	20TCr
NOVO NORDISK A/S	-1.60%	-5.51%	-22.30%	-58.60%	19TCr
GILEAD SCIENCES, INC.	+0.49%	-0.23%	+30.00%	+93.34%	18TCr
Average	-0.25%	-1.31%	+22.94%	+39.36%	35.64TCr
Weighted average by Cap.	+0.41%	+0.01%	+34.52%	+59.42%

	2026 *	2027 *
Net sales	4.42Cr 45.27L 39.21L 37.08L 33.57L 63L 43Cr 63.48L 1.7Cr 22Cr 1.7Cr 1.66Cr 70Cr	2.16Cr 22.1L 19.14L 18.1L 16.39L 30.75L 21Cr 30.99L 83.1L 11Cr 83.01L 81.17L 34Cr
Net income	-4.71Cr -48.17L -41.73L -39.46L -35.72L -67.04L -46Cr -67.55L -1.81Cr -23Cr -1.81Cr -1.77Cr -75Cr	-3.19Cr -32.66L -28.29L -26.75L -24.22L -45.45L -31Cr -45.79L -1.23Cr -16Cr -1.23Cr -1.2Cr -51Cr
Net Debt	2.48Cr 25.38L 21.99L 20.79L 18.82L 35.33L 24Cr 35.59L 95.45L 12Cr 95.34L 93.23L 39Cr	7.42Cr 75.93L 65.77L 62.19L 56.31L 1.06Cr 73Cr 1.06Cr 2.86Cr 37Cr 2.85Cr 2.79Cr 117.78Cr